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Max von Pettenkofer-Institute for Hygiene and Medical Microbiology, University of Munich, Munich, Western Germany 
Epstein-Barr virus (EBV) causes infectious mononu-
cleosis as a primary disease. The virus infects more than 
90% of the average population and persists lifelong in 
peripheral B-lymphocytes. The virus is produced in the 
parotid gland and spread via the oral route. Serology 
suggests that the Epstein-Barr virus might be involved 
in the causation of two neoplastic diseases of humans: 
African Burkitt's lymphoma and nasopharyngeal car-
cinoma. Whereas the development of the lymphoma has 
an even better linkage with chromosomal rearrange-
ments, nasopharyngeal carcinoma shows a unique asso-
ciation with Epstein-Barr virus. Environmental factors, 
including traditional Chinese medicine, may be respon-
sible for the enhanced risk of nasopharyngeal carcinoma 
in certain, predominantly Chinese, populations of south-
ern Asia. Possible mechanisms leading to the establish-
ment of the neoplastic manifestations will be discussed. 
E p s t e i n - B a r r v irus ( E B V ) , pap i l l oma virus , and hepatitis B 
virus have a few remarkable properties i n common. T h e i r 
mobile nucleic ac id is D N A that is c i rcular or integrated during 
latency, they persist l i fe long i n carriers, and they resisted a l l 
attempts to grow them i n v i tro i n a simple and fully lytic 
system. T h e y are, however, eff iciently t ransmit ted i n nature, 
where they may cause a more or less severe pr imary infection 
followed by a l i fe long carrier status, ind icat ing the delicate 
interact ion of these viruses w i t h the ir hosts. E B V * was first 
isolated and characterized as a herpes group virus from l y m -
phoblasto id cell l ines of the B lineage established from Afr i can 
B u r k i t t ' s lymphomas ( B L ) . V i r a l partic les or structural a n t i -
gens have never been detected i n fresh biopsies. T h e possibil ity 
to grow these cell l ines from the neoplastic tissue was not only 
technical ly very helpful , because these cells could be used as an 
antigen source for serologic studies, but it was also supposed to 
be a signif icant observation as far as the mechanisms of onco-
genicity are concerned. T h e role of E B V i n this process was 
stressed by the fact that B cells of n o r m a l u m b i l i c a l cord blood 
are efficiently immorta l i zed by preparations of E B V . W h e n 
some years after these i n i t i a l f indings marmosets died of i y m -
phoproli ferative disease after inoculat ion w i t h E B V , it ap-
peared as i f the H e n l e - K o c h postulates for the causation of a 
neoplastic disease of humans by a v irus had been fulf i l led for 
the first t ime. 
However , i f one looks to the H e n l e - K o c h postulates in their 
or ig inal version w i t h a l l their l imi ta t i ons , especially for assess-
ing secondary or chronic disease, one can see that the situation 
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A b b r e v i a t i o n s : 
B L : B u r k i t t ' s l y m p h o m a 
E A : early antigens 
E B N A : E p s t e i n - B a r r nuclear antigen 
E B V : E p s t e i n - B a r r virus 
N P C : nasopharyngeal carc inoma 
P B L : per iphera l b lood lymphocyte 
T C : T o n s i l l a r carc inoma 
V C A : V i r a l capsid antigens 
* M o s t of the data presented i n the f irst par t of th i s paper are 
extensively referenced i n available review l i terature [1-3] . 
should not be seen as s impl i s t i c . T h e H e n l e - K o c h postulates 
(in a t rans lat ion of R ivers [4]) are as follows: 
1. T h e parasite occurs i n every case of the disease i n question 
and under c ircumstances that can account for the patho-
logic changes and c l in i ca l course of the disease. 
2. It occurs i n no other disease as a fortuitous and nonpath-
ogenic parasite. 
3. Af ter being fully isolated from the body a n d repeatedly 
grown in pure culture, it can induce the disease anew. 
For A f r i can B L , the f irst postulate is not fu l f i l l ed in only 3% 
of cases. However , c l in i ca l ly very s i m i l a r lymphomas outside 
Afr ica—where they are m u c h r a r e r — c a n be associated with 
E B V i n only 2 5 % of cases. T h i s w i l l be commented on later. 
T h e second postulate is not exactly fu l f i l l ed because E B V is 
regularly associated w i t h infectious mononucleosis , cl inically 
inapparent seroconversion and nasopharyngeal carc inoma. The 
t h i r d postulate is also not ful f i l led i n its str ict sense because 
the experimental ly infected marmosets present w i t h a poly-
clonal , although fatal , lymphopro l i ferat ive disease. T h i s obser-
vation w i l l also be commented on later. 
S E R O L O G Y O F E B V - R E L A T E D D I S E A S E S 
T h e B-ce l l l ines that can be establ ished from B L or, as was 
shown later, f rom anybody's per ipheral b lood leukocytes after 
pr imary E B V infect ion vary in their ab i l i ty to produce virus, 
although every single cell contains E B V genomes a n d expresses 
a nuclear antigen, E B N A . Some cell l ines , e.g., one named Raji, 
can be treated w i t h a variety of chemicals , such as I U D R , 
butyric acid, phorbol esters, or cycloleucine. A l l these com-
pounds are inhibi tors of D N A - m e t h y l a t i o n and induce synthe-
sis of addit ional v irus-re lated antigens that have been named 
early antigens ( E A ) . Only few cell l ines stably produce virus 
and v i ra l capsid antigens ( V C A ) by spontaneous act ivat ion of 
the latent genome i n a characterist ic f ract ion of the cells. The 
various cel l lines proved of tremendous value for molecular 
biology and seroepidemiology. U s i n g these antigens, the Henles 
and a number of other investigators found that B L patients 
had invariably h i g h antibody levels to E B V - r e l a t e d antigens. 
The seroconversion to E B V pos i t iv i ty of one laboratory tech-
nic ian following severe mononucleosis was the in i t ia tor of a 
study w i t h college students at Y a l e that clearly showed that 
E B V is the cause of infectious mononucleosis a n d that this 
frequent disease o f higher socioeconomic groups is the primary 
disease caused by E B V . 
Sera from nasopharyngeal carc inoma revealed s i m i l a r E B V 
specific antibody patterns to those observed for B L . Sera from 
a variety of other diseases (Hodgkin ' s disease, chronic lym-
phatic leukemia, chronic myelon leukemia , and sarcoidosis, just 
to name some) also showed s igni f i cant ly elevated antibod} 
titers. However, i n a l l these cases, a s igni f i cant f ract ion of sera 
was negative and antibody levels to other latent viruses (vari 
cella v i rus , cytomegalovirus) were also elevated. 
I N F E C T I O U S M O N O N U C L E O S I S A S T H E P R I M A R Y 
D I S E A S E C A U S E D B Y E B V 
Infectious mononucleosis seems to be u n k n o w n i n such areas 
as the Phi l ipp ines [5] or M a l a y s i a [6], where infect ion by E B V 
occurs very early i n life and almost everybody has antibodies 
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by he age of 10 years. C l i n i c a l symptoms seem to be a conse-
qu nee of juvenile or adu l t infect ion, and one might speculate 
wh >ther a vacc ine -pr imed organism w i l l be infected without 
Se\ are c l in ica l symptoms . 
' 'he c l in ica l diagnosis of infectious mononucleosis is usual ly 
dei ived from a c o m b i n a t i o n of four signs: 
. H i g h leukocyte count ranging from 10,000 to 20,000 and 
reaching up to 50,000 
::. 10% atypical cells 
;;. L y m p h a d e n i t i s 
4. Fever 
The most frequent symptoms are listed in Table I. 
T A B L E I. Clinical symptoms of infectious mononucleosis 
Symptom Incidence 
Enlarged l y m p h nodes 80 -100% 
Fever 85 -98% 
P h a r y n g i t i s 8 0 - 9 5 % 
T o n s i l l i t i s 9 0 - 9 8 % 
Splenomegaly 40 -90% 
Hepatomegaly 30 -40% 
Per i o rb i ta l edema 10 -30% 
E n a n t h e m a 3 0 - 5 0 % 
E x a n t h e m a 3 -15% 
Jaundice 5 -10% 
Source: M o d i f i e d f rom [7]. 
Several authors described a much higher prevalence of rash. 
T h i s is, however, i n most cases due to a typ ica l concomitant 
hypersensit ivity to a m p i c i l l i n . A b o u t 1 percent of the infectious 
mononucleosis cases show one or more of the compl icat ions 
l isted in Table II, either already at the onset of the disease or 
as a late consequence. M o s t compl icat ions are due to a u t o i m -
mune mechanisms a n d are i n some cases indiscernible from 
graft versus host disease, a mechanism by w h i c h the body could 
clear itself from the excess of E B V - c o n v e r t e d pro l i f erat ing B 
cells. 
Under rare circumstances, the T - c e l l response might be i n -
sufficient because of temporary influences such as treatment 
w i t h high doses of cyclosporin A i n combinat ion w i t h cort ico-
steroids or because of A I D S or a certain genetic predisposi t ion 
as described by P u r t i l o et a l (Duncan 's syndrome, X L P , X -
chromosome- l inked lymphoprol i ferat ive disease) [9]. In these 
cases, occasional B cells have a chance to escape host contro l 
and grow without l i m i t a t i o n , as they do when they are kept i n 
vitro . T h e consequences have been described as B L - l i k e disease 
in 3 A I D S patients [10] or as po lyc lonal lymphoprol i ferat ive 
disease for X L P patients [9] or kidney t ransplant recipients 
[ in . 
T h e first standard test for the diagnosis of infectious m o n -
onucleosis is s t i l l the test for heterophile antibodies when 
specific tests are not available. F o r young ch i ldren , these tests 
are false negative i n up to 30% of cases. E B V - s p e c i f i c antibodies 
T A B L E II . Complications of EBV infection 
1. Hematologic : Agr anu lo cy tos i s , granulocytopenia, auto immunohe-
molyt ic anemia, thrombocytopen ia , panmyelopathy 
2. Hepat i c : Hepat i t i s , massive necroses 
3. Neurologic : Cerebe l l i t i s , encephal it is , G u i l l a i n - B a r r e syndrome, 
meningoencephal i t is , transverse myel i t i s , S S P E 
4. R e n a l : G l o m e r u l o n e p h r i t i s , nephrot ic syndrome 
5. Cardiovascular : M y o c a r d i t i s , per icardit is 
6. Respiratory : A c u t e la ryng i t i s , in ters t i t ia l pneumonia , bronchopneu-
m o n i a 
7. Others : A r t h r i t i s , dermat i t i s , splenic rupture, immunodef ic iency, 
myoglobinuria , subacute thyro id i t i s , t rans i tory anergia 
8. Neoplast i c : Convers ion o f po lyc l ona l B - c e l l pro l i ferat ion to mono-
c lonal B - l y m p h o b l a s t mal ignancy 
0 X L P as an example o f immunolog i ca l ly depr ived hosts. 
b De termined by i m m u n o p r e c i p i t a t i o n of G P 240/200. 
T A B L E III. Serologic parameter associated with various disease 
conditions 
V C A 
Disease - - E A E B N A M A " 
IgG IgM IgA 
N o r m a l adults + — - - + + 
Acute adults (early) ++ + - + - -
C h r o n i c infect ion + + - ± ± ± 
React ivat ion + + - + + + 
X L P 7 + - - + (+) 9 
N P C ++ - + +(D) + + + 
B L ++ - - +(R) + 4-
F I G 1. In situ E B V D N A h y b r i d i z a t i o n 
)f cryosections of n o r m a l p a r o t i d g land 
a, b), n o r m a l tonsi l (c), and n o n k e r a t i n -
zing t ons i l l a r carc inoma (d). C l o n e d 
v W D N A that was labeled i n v i t ro w i t h 
! ' l ] t h y m i d i n e t r iphosphate by nick 
n n s l a t i o n was used as a probe. Note 
I at the producing cells (arrow) in the 
); rot id glands surround or are present 
r the ducts (a, b), that the n o r m a l tons i l 
s EBV-genome- f ree (c), a n d that the 
( as i l lar carc inoma conta ins E B V - c a r -
"Ung cells (arrow) (d). (From Wolf et al 
a 
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vary in their value for diagnosing disease. Table III gives the 
appearance and persistence of the antibodies with their respec-
tive reactivities. 
There is no cure for infectious mononucleosis other than 
time, although the clinical symptoms and the antibody titers 
reportedly reach normal values much faster, especially in severe 
cases, when the tonsils are removed [12]. The tonsils may be 
the primary site of immunologic defense and the reservoir or 
"recruitment center" of B-lymphocytes able to proliferate. F o l -
lowing convalescence, about 0.01% of B cells supposedly con-
tain E B V genomes or E B N A and are able to grow in vitro. The 
chances of growing EBV-immortal ized B cells are higher i f 
leukocyte preparations are infected with certain strains of E B V 
(e.g., from the B-95-8 marmoset cell line). When this in vitro 
immortalization is done with leukocyte preparations from 
EBV- immune individuals, the T cells have to be removed. A t 
least 60% of patients with infectious mononucleosis shed E B V 
in their saliva. Virus shedding does not require special preven-
tion against spreading the disease because epidemics are rare 
and infection of persons in close contact (roommates) is scarce 
[13]. Virus shedding does not stop with recovery from disease, 
and at least 30-40% of the adult population sheds E B V . 
N A S O P H A R Y N G E A L C A R C I N O M A A S A P O S S I B L E 
" S E C O N D A R Y D I S E A S E " R E L A T E D T O E B V 
The other disease in which E B V so far shows a 100 percent 
association is nasopharyngeal carcinoma (NPC) [3]. N P C most 
frequently starts at the fossa rosenmuelleri at the postnasal 
space, although patients frequently report only after the first 
typical metastases in the cervical lymph nodes have developed. 
The disease has an incidence of up to 40 per 100,000 per year, 
the most frequent neoplasia of humans occurring in some areas 
of southern China and among Chinese in Singapore and M a -
laysia. The incidence is also elevated in other parts of the 
world, such as Borneo or Tunisia. In most other areas, the 
incidence is around 0.2 per 100,000 per year. The age distribu-
tion shows a clear single peak around the ages of 40 to 50 in 
almost all high-risk areas. There is, however, a second peak at 
an early age, ranging from 5 to 15 years in Borneo and to some 
extent in Tunis ia [3]. Possible exogenous risk factors wi l l be 
discussed later. A genetic disposition for the disease is difficult 
to test, although the decline of tumor incidence in second-
generation Chinese emigrants to the United States, expecially 
if they live in rural areas, does not support a genetic involve-
ment [1-3]. The relatively simple H L A patterns of the Chinese 
allowed, however, a significant association of relative risk with 
certain H L A types. A2 and B W 4 6 have elevated relative risks 
of 1.5 and 1.9, respectively, and of 2.5 i f expressed in combi-
nation, and B 1 7 / B W 5 8 is associated with a relative risk of 2.2. 
A l l , however, is associated with a relative risk of 0.5. Thus a 
relative risk factor of 5.0 exists between the best and the worst 
constellation of H L A types [14]. The neoplasia leads invariably 
to death of the patient, frequently with extensive cranial inva-
sion unless the tumor is recognized early and treated. The most 
successful therapeutic approach is early detection combined 
with careful radiation [15], and survival rates exceeding 90% 
have been reported (Yi Zeng, personal communication). The 
use of inexpensive screening methods becomes evident in face 
of the correlation between a rapid decline in survival rates and 
the elapsed time between the putative earliest detection with 
careful screening and the actual detection of disease and first 
intervention. The determination of IgA a n t i - V C A antibodies 
has been used with good success to define a group at high risk, 
since 3% of persons positive in this test had N P C upon clinical 
examination. Between 35 and 70% of tumor bearers have IgA 
antibodies to E A ; therefore, this test can be used with good 
success as a second screening step. About 30 percent of patients 
positive in the IgA a n t i - E A test have detectable N P C [43]. New 
and improved methods for the detection of viral nucleic acid 
and the development of sampling devices that aspirate cells 
without taking biopsy [16] may further improve the diagn< tic 
possibilities. The introduction of single-stranded hybridiza on 
probes and the availability of label other than V2P with its 
inhibitory short half-life have helped to bring nucleic acid 
hybridization over the threshold of a routinely usable method. 
Considering cost-effectiveness, necessary equipment, and sen-
sitivity, we have found that chemical iodination of a collection 
of viral fragments cloned in the single-stranded D N A phage 
m l 3 gives excellent hybridization probes usable for in situ 
hybridization and hybridization on Southern blots of D N A or 
spotted D N A or cell lysates [44]. 
B U R K I T T ' S L Y M P H O M A A N D I T S A S S O C I A T I O N 
W I T H E B V 
Burkitt ' s lymphoma has been discussed earlier, and addi-
tional remarks wi l l be found in the Discussion section. 
SERUM ND 6 5 6 6 7070 8463 
EBNA - 16 32 32 
EA - - 4096 -
VCA - 2042 16384 1024 
F I G 2. A n analysis of EBV-spec i f ied polypeptides by immunopr 
cipitation using sera with different reactivities to EBV-spec i f ied an 
gens. N D is a serum free of E B V antibodies; 6966 and 8463 have hn 
titers against V C A but not E A ; serum 7070 has high titers against bo 
V C A and E A . Proteins 138, 88, 45, 40, 38, and 37 are only precipitate 
by the EA-posit ive sera. These results are representative for a mu< 
larger panel of sera which we have tested. (From Bayliss and Wc 
[30].) 
F I G 3. a, R N A from induced P 3 H R 1 was hybridized to the cloned E B V Bam fragments and two clones ( M 3-1-1 and M 3-5-6) that subdivide 
the Bamk fragment (see map). The bound m R N A was eluted and translated in vitro using the rabbit reticulocyte system. The translation 
products were immunoprecipitated and analyzed on SDS-polyacrylamide gels. 
S O M E O P E N P R O B L E M S A N D A P P R O A C H E S T O 
S O L V I N G T H E M 
The presented observations on the involvement of E B V with 
] leoplastic and nonneoplastic disease raised a number of ques-
1 ions that wi l l be discussed in this section: 
1. What is the source of virus in the throat washings of 
apparently healthy persons, and why do apparently nor-
mal individuals who shed virus have antibodies only to 
V C A and E B N A and not to E A , which are produced in 
large amounts during viral replication? 
2. How does the virus infect epithelial cells that apparently 
lack receptors for the virus? 
3. How does the virus persist in cells lifelong, and what are 
the molecular mechanisms underlying the regulated 
expression of E B V ? 
1. One might postulate that E B V - c a r r y i n g lymphocytes in 
the oropharynx that may have escaped host control mecha-
nisms could be the source of the virus that can be obtained 
from healthy individuals. Other studies [17] indicated that E B V 
could be isolated in relatively high titers from saliva collected 
P R O T E I N S IN I N D U C E D R A J I C E L L S 
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F I G 3. b, M a p of the in vitro translated proteins with hybrid-selected R N A from induced P 3 H R 1 cells and induced Raj i cells. The Bam 
fragments were cloned from B 95-8 derived E B V D N A . By hybridizing to sheared fragments of E B V D N A cloned in Charon 4A, a finer map of 
the coding regions of some proteins could be achieved. The narrow coding regions for proteins 18, 90, 47, 73, and 69 in the induced Raj i cells are 
based on the assumption that these proteins correspond to proteins with the same molecular weights in P 3 H R 1 cells. 
from Stenson's duct. Studies on parotid salivary gland tissue 
[18,19] have suggested that the cells which surround or f i l l the 
lumen of the ducts of this gland are capable of supporting a 
productive cycle of E B V replication (Fig 1, a, b). Production of 
E B V in salivary duct cells could also explain the absence of 
certain EBV-speci f ic serum antibodies in normal adults (see 
also Discussion). Searches with other tissues of the oropharynx 
(e.g., tonsils from healthy individuals; Fig 1, c) proved negative, 
since no productively infected cell could be found using in situ 
hybridization techniques. This situation resembles somewhat 
that seen with Marek's disease virus, where the transformed 
cells are T cells, but the lytic expression of the virus occurs in 
the germinative epithelium of the feather follicles [20]. In situ 
hybridization studies using tonsillar carcinoma (TC) tissue, 
however, showed that 25% of the specimens tested so far carried 
E B V D N A in the epithelial cells (Fig 1, d). 
2. To date, receptors for E B V have been demonstrated only 
on B-lymphocytes [21] and no other normal nonmalignant cell 
type [3]. How then does the virus enter such cells and persist 
within them? Initially, microinjection of E B V D N A into a wide 
variety of receptor-negative cells [22] and, later, transfection 
with E B V D N A using the calcium phosphate coprecipitation 
technique [23,24] and the implantation of receptors into the 
membranes of receptor-negative cells [25] have been used to 
demonstrate that once E B V overcomes the barrier of penetra-
tion, normal expression of the virus can occur, although syn-
thesis of E B N A was not observed when only lytic expression 
was induced. It was proposed some time ago that syncitium-
inducing viruses, such as paramyxovirus, might induce fusion 
between lymphocytes and epithelial cells, thus allowing the 
virus to gain access to such cells. Since then, we have demon-
strated that E B V itself can induce fusion. When densely packed 
monolayers of lymphoblastoid cells [26] were infected with 
E B V derived from the EBV-producing cell line P 3 H R 1 , the 
formation of polykaryocytes could be observed. Further studies 
with mixed monolayers containing both receptor-positive (Raji) 
cells and receptor-negative cells (human fibroblasts, epithelial 
cells, or T-lymphoblastoid cells) showed that an infected E B V -
antigen-expressing B-lymphoblastoid cell was capable of fusing 
with a noninfected receptor-negative cell [27]. A close cell-to-
cell contact, such as occurs in monolayers, is necessary for the 
development of polykaryocytes. The viral nature of the fusion 
event and the mechanisms involved have been studied in detail 
using chemical activation of latent genomes and various met-
abolic inhibitors. It was shown that an early viral protein was 
responsible for the fusion event [28]. More recent experiments 
[29] have further substantiated the viral origin of the fusion-
inducing protein(s). Purif ied E B V D N A was transfected into 
unrelated cells ( N I H 3T3 cells). In addition to the synthesis of 
E B V E A , fusion of the transfected cells was also observe 1. 
Further studies with this technique using cloned fragments f 
the E B V genome should permit the mapping of gene(s) encod-
ing the fusion on the E B V genome [29]. 
3. Very little is known at the molecular level of the mecb 
nisms that regulate the response of the cell to infection wi-
E B V . As far as we know, all E B V - c a r r y i n g cell lines expres; 
single viral a n t i g e n — E B N A . This protein could be the repr< 
sor protein that prevents lytic expression. If E B V - c a r r y i n g c 
lines are infected with a sufficiently high multiplicity, a ly 
cycle wil l occur [30], during which at least 30 virus-induced 
specific proteins wi l l be synthesized. These proteins can 
divided into three groups according to their kinetics of syntl 
sis, response to inhibition of D N A synthesis, and requireme 
for virus-specified factors. 
Do these observations have any relevance to regulat 
expression of E B V during the stepwise induction of a lytic eye 
by the virus in the absence of inhibitors? If Raj i cells t 
infected with decreasing amounts of virus, then the intern 
diate and late proteins are no longer synthesized at a cert; 
cutoff value [29,31]. 
However, a certain subset of the E A complex is made, and it 
is the same subset as that obtained by chemically induced Raji 
ctlls. Similar observations have been made using an E B V 
grnome-negative cell line (BJA) . Immunoprecipitation of E B V 
p oteins allows further characterization and a linkage to sero-
lcgic data. These data (Fig 2) show also that proteins of the 
EA complex are synthesized in considerable amounts during 
the replication of E B V ; yet normal adults do not have antibod-
ies against these proteins even if they shed virus. 
In an attempt to substantiate further the viral nature of the 
polypeptides and to map the genes on the viral genome, both 
of which are essential for detailed studies of the molecular basis 
for regulation of viral gene expression, we selected m R N A from 
a producer cell line (P3HR1) by hybridization to cloned E B V 
D N A fragments. This m R N A was then translated in vitro using 
a rabbit reticulocyte translation system. W i t h this technique 
we were able to identify proteins as EBV-specif ic and have 
mapped their positions on the E B V genome (Fig 3, a, b) (Rudolf 
Seibl and Hans Wolf, in preparation). 
One interesting observation that awaits explanation is that 
if m R N A from EBV-negative cells ( B J A - B ) is selected using 
E B V D N A , an m R N A is obtained that hybridizes to the BamHl 
K fragment of the E B V genome. This R N A can be translated 
in vitro to yield polypeptides of 84 kd and 92 kd molecular 
weight (Fig 4). This region of the E B V genome is known to 
hybridize to cellular D N A under stringent conditions and may 
Bam R K B 
F l G 4. R N A from B J A - B cells was hybridized to cloned Bam frag-
ments of E B V as given on top of the gel slots. The bound m R N A was 
eluted and translated in vitro. Translat ion products were analyzed on 
SDS-po lyacry lamide gels. 
represent cellular sequences that have been incorporated into 
the viral genome during the course of evolution. 
D I S C U S S I O N 
A model has been developed that attempts to include the 
available data and should be useful to predict certain events or 
measurable parameters as well as to design further experiments, 
thus allowing the hypothesis to be further tested (Fig 5). 
1. Normal Situation 
a. Primary infection: Development of antibodies to V C A , E A , 
and E B N A 
As suggested, E B V infects B-lymphocytes during acute or 
primary infection, and because of the lack of immune response, 
a number of cells enter into the lytic cycle and produce a full 
set of viral antigens (EA and V C A ) that are shed into the 
bloodstream. It seems probable that not all B-lymphocytes are 
capable of supporting a fully lytic infection because of a cellular 
factor that prevents expression of E B V (Fig 5, block 2). These 
cells wi l l be selected for and grow on to become the cells that 
carry E B V latently for the rest of the host's life. 
Because of the release of al l the EBV-speci f ied antigens, 
antibodies wi l l be developed against E A , V C A , and E B N A 
(Table III). 
b. Convalescence: Disappearance of antibodies to E A and 
maintenance of antibodies to V C A and E B N A 
As the immune defense mechanisms of the body remove the 
lytically infected cells from the circulation (Fig 5, block 2), the 
antibody levels wi l l start to fall during the convalescent phase. 
After a certain period, antibodies to the E A disappear. However, 
as mentioned above, E B V is produced in the parotid gland. The 
viral particles and intracellular virus-associated antigens i n -
cluding E A wil l be shed into the saliva and reach the orophar-
ynx. Here the viral particles (but not E A ) could bind to the B -
lymphocytes and be presented to the body as antigens, thus 
maintaining the antibody titers to V C A . E A cannot bind to the 
lymphocytes and wil l be degraded by proteases and not be 
available to the body as antigens. Circulating lymphocytes that 
carry E B V latently contain E B N A and as far as we know no 
other EBV-specif ied protein. These lymphocytes wi l l be subject 
to the normal turnover processes, and as they die, they wi l l 
release E B N A into the bloodstream. Therefore, antibodies to 
this antigen wil l persist. As a consequence, normal convalescent 
sera wil l have low-level IgG a n t i - V C A and a n t i - E B N A antibod-
ies (Table III). 
2. Special Conditions 
a. Nonspecific secondary antibody titer increase to V C A and 
E A 
If immunosuppression occurs, either because of other disease 
(e.g., Hodgkin's disease) or because of immunosuppressive ther-
apy, some of the circulating peripheral blood lymphocytes 
(PBLs) wi l l escape the normally tight control mechanism and 
enter into a cycle of virus replication, causing a secondary 
increase in the titers to E A , V C A , and E B N A . 
b. Development of Burkitt ' s lymphoma (monoclonal disease) 
Under rare circumstances, a cell clone that differs in its 
antigenic makeup may arise and be selected. Th is clone may 
then lead to the development of B L . Environmental mutagens 
[32] and unspecific "mitogens" (malaria) [33] that facilitate 
clonal selection through proliferation may favor this event. 
Specific karotypes in the selected clones may correlate to the 
altered antigenic makeup of these cells. 
Following original observations by Manolova et al [34], sev-
eral authors have indicated that chromosomal rearrangements 
occur in all B L cases independent of their association with 
E B V [35]. The most important step seems to be a translocation 
0 0 0 
cell lysis 
V C A 
• 
EA 
immunol el imination 
cytogenetic error 
clonal seletion 
Lymphoepithelial Carcinoma 
of Waldeyer s ring 
(main ta inance 
of populat ion) 
E B N A 
cytogenetic error 
unspeci f ic stimulation 
clonal selection 
FlG 5. The scheme summarizes the 
suggested biological effects of E B V de-
scribed in the text. Blocks 1 and 2 inhibit 
the lytic expression of E B V , and block 3 
suppresses the proliferation of E B V gen-
ome containing lymphoid cells in the 
periphery. Block 1, B lock at cellular level 
(endogenous block). Evidence: Only a 
certain percentage of cells from cloned 
cell lines produce virus. T h i s block is 
responsible for poor production of virus. 
Block 2, Block from the outside (exoge-
nous block, immunologic control?). Evi -
dence: In peripheral blood from patients 
with infectious mononucleosis, in fresh 
B L or N P C biopsies no viral particles 
can be found. After explantation into 
tissue culture, a few cells start to produce 
virus. O : E B V , O: activated E B V genes, 
v: E B V r e c e p t o r s , ^ : virus-specific 
changes. (From Wolf et al [29].) 
Lymphoma 
of part of the distal arm of chromosome 8 carrying the cellular 
oncogene myc to alternate acceptor chromosomes 2, 14, or 22, 
respectively. The oncogene is in all cases translocated to a 
transcriptionally active site close to immunoglobulin genes. 
Whether the transcription of the myc gene after translocation 
is enhanced and what impact this may have are not clear yet 
[36,37]. In any case, the involvement of myc alone cannot 
explain the patterns or mechanisms of appearance of B L . 
It should be noted that all E B V genomes containing B -
lymphoblastoid cells have unlimited growth potential in vitro 
and after intracerebral injection into nude mice. Only the 
lymphoma-derived cells, however, can grow in the nude mouse 
after subcutaneous application [3]. This behavior seems rather 
suggestive of a loss of control elements on the surfaces of the 
selected clones. One might speculate that H L A or similar 
determinants are altered or lost during the process of clonal 
selection. 
Transfection experiments have shown that two oncogenes 
frequently may be involved in oncogenesis [38]. Such a model 
could include an E B V gene as a possible member of a comple-
mentation group of oncogenes and myc as a member of another 
group. Thus E B V might st i l l play a major role in the causation 
of African B L . 
c. Development of polyclonal proliferative disease 
Specific genetic constellations ( X L P ) or acquired conditions 
(immunosuppressed transplant recipients, A I D S patients; see 
above) determine a reduced efficiency of block 3 (cellular re-
sponse to proliferating cells). Therefore, the selective pressure 
on peripheral B-lymphocytes (which already have a potential 
for unlimited growth by virtue of the resident E B V genomes) 
may be weaker. Under less stringent selective pressure, more 
cells may proliferate in vivo and lead to a polyclonal lymphoma 
[9]. Nonspecific growth stimuli such as the graft may favor 
initial proliferation and facilitate the selection of cell clones. A 
specific cytogenetic error [39] may occur under therapy and 
may induce a change from polyclonality to monoclonality. 
d. Relation to T-cel l leukemia 
As a side effect of primary E B V infection, the init ial prolif-
eration of B-lymphocytes due to the early absence of block 2 
apparently leads to a proliferation of T-lymphocytes [8]. This 
may well be caused by growth factors. This polyclonal activa-
tion of T-lymphocytes may occasionally activate T cells with 
malignant growth potential and lead to a T-cel l leukemia 
following infectious mononucleosis. 
e. Development of nasopharyngeal carcinoma 
On the specific conditions of the site of initiation of lym-
phoepithelial tumors. A close contact between epithelial cells 
and B-lymphocytes that may carry E B V genomes has been 
described for the lymphoepithelial ring of the throat (Waldey-
er's ring). Th is unique tissue may provide the necessary con-
ditions for EBV- induced fusion between the two cell types, thus 
enabling the E B V genome to enter the epithelial cells. If this 
hypothesis is true, then E B V should be associated with other 
tumors that arise within this tissue. Evidence for this associa-
tion has been independently derived by our group [28] and by 
Brichacek et al [40]. The major difference between T C and 
N P C is that only 25% of the limited number of T C s so far 
tested were serologically related to E B V , whereas al l N P C s are 
EBV-genome-positive. A t the moment, we cannot explain these 
findings. Th is proposal would be in good agreement with the 
proffered model. 
On the role of environmental factors on the relative risk ol 
N P C . It has been observed that certain plant extracts car 
induce latent E B V and somehow increase the risk for NP( 
[41]. Croton oi l was one of the first suspected medications 
However, it is highly irritating and is used only under clos* 
medical supervision and is therefore unlikely to be an N P C 
related risk factor. More recently, Zeng et al [42] have teste-
over 500 different extracts from 100 plant families and foum 
that 20 of them were capable of activating latent E B V . Som 
of the extracts were active as aqueous extracts and thus oper 
the possibility that traditional Chinese herbal medicine, ofte 
applied as teas, may contain E B V - i n d u c i n g principles. On 
difference in the E B V serology of the populations with low an« 
high risk for N P C development is that in high-risk areas t h 
level of antibody to E B V antigens remains high throughout lit 
when compared with low-risk populations (Y i Zeng and Sh 
Y a n G u , personal communication). Thus EBV-ac t ivat ing sub 
stances could continuously stimulate the latently infected I 
cells to enter into a lytic cycle, explaining the differences i 
a itibody titers. If follow-up studies could demonstrate a match 
b .tween the areas with high risk for N P C and the use of the 
d scussed plant extracts, a multifactorial causation of N P C 
w ould be substantiated. 
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